tnp-2198
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started May 9, 2019 (NCT06081699)
Timeline
Indications
Studied for
Mechanism of action
- DNA-directed RNA polymeraseINHIBITOR
DNA-directed RNA polymerase inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06551623 | Phase 1 | Aug 26, 2024 | Jinlin University, TenNor Therapeutics Ltd |
| NCT05857163 | Phase 3 | May 18, 2023 | TenNor Therapeutics Ltd |
| NCT06137573 | Phase 1 | Jul 12, 2022 | TenNor Therapeutics Ltd |
| NCT06076694 | Phase 2 | Jun 26, 2022 | TenNor Therapeutics Ltd |
| NCT06076681 | Phase 1/Phase 2 (Phase 2) | Sep 27, 2021 | TenNor Therapeutics Ltd |
| NCT06081712 | Phase 1 | Oct 20, 2020 | TenNor Therapeutics Ltd |
| NCT06081699 | Phase 1 | May 9, 2019 | TenNor Therapeutics Ltd |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TenNor Therapeutics Ltd | For profit | 7 | 7 | 3 | 2019 |
| Jinlin University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1